Enjoy complimentary customisation on priority with our Enterprise License!
The Digital Biomarkers market size is projected to grow by USD 4.42 billion at a CAGR of 21.04% from 2023 to 2028. Market growth is primarily driven by the increasing prevalence of neurological disorders and cardiovascular diseases (CVDs), necessitating advanced diagnostic and management solutions. These digital biomarkers are used for monitoring health metrics in real time through healthcare wearables, enhancing proactive healthcare management and facilitating early intervention strategies.
To learn more about this report, Request Free Sample
The global digital biomarkers market is expanding across therapeutic areas such as Parkinson's disease and cardiovascular disease, driven by the rising prevalence of chronic diseases. Demand for digital biomarkers is fueled by advancements in wearable devices and digital devices, enabling real-time monitoring of health data. Key players in the digital biomarkers industry leverage artificial intelligence to analyze these biomarkers, enhancing clinical trials and treatment efficacy. The market report highlights significant trends in the adoption of digital biomarkers, indicating a growing segment expected to revolutionize healthcare with innovative solutions for personalized medicine and proactive health management.
The Market is segmented based on various factors related to hospital patients and their specific health needs. This includes considerations for patients with chronic diseases and critical health concerns, especially among the aging population. Monitoring vitals, patientspecific parameters, and physiological data is crucial for providing timely treatment and proactive healthcare. Digital biomarkers also encompass behavioral data, such as sleep patterns and physical activity, which are vital indicators of emotional health and overall well-being. The use of wearable devices facilitates the collection of biometric data like glucose levels, blood pressure, and heart rate, enabling continuous monitoring and personalized interventions. Additionally, the market considers telemedicine and virtual consultations as key components of digital healthcare delivery, bridging geographical gaps and improving access to healthcare services. Future potential lies in leveraging digital tools and technologies to enhance wellness activities and address specific health concerns such as neurological disorders and respiratory disorders, there is growth of neurological biomarker.
The market share growth by the healthcare companies segment will be significant during the forecast period. Digital biomarkers help healthcare companies in conducting clinical trials, developing precision therapies, and many others. Clinical trials test the safety and efficacy of medical treatments, therapies, and devices.
Get a glance at the market contribution of various segments View a PDF Sample
The healthcare companies segment was the largest and was valued at USD 610.10 million in 2018. Approximately 20% of all cancer clinical trials fail because of insufficient patient enrollment. Meanwhile, clinical trials without appropriately representative participants may fail to assess potential adverse side effects in relevant subsets of the population, such as racial/ethnic minority groups. Among the many obstacles to effective participation in clinical trials are location, travel expenses, distrust, stringent qualifying requirements, and time constraints. Using biomarker tracking to monitor patients remotely can help remove some of these obstacles to participation in clinical trials. According to the US government, there are other advantages to remote patient monitoring, such as decreased chances of infection and illness, lower hospitalization rates, and improved management of chronic health conditions. Thus, the adoption of digital biomarkers by healthcare companies involved in clinical trials will drive the growth of the segment and the market in focus during the forecast period.
Wearables offer continuous monitoring and data reporting through devices that patients wear physically on their bodies. Real-time physiological data, including heart rate, blood pressure, and activity levels, can be recorded by wearables like smartwatches and fitness trackers. These devices are also capable of tracking behavioral data such as emotions and sleep patterns. Moreover, changing consumer preferences, changing lifestyles, and increasing geriatric population are factors that have led to the growing prevalence of chronic diseases such as diabetes, heart ailments, and cancer, thereby driving the adoption of wearables. Thus, such factors will drive the growth of the segment and, in turn, the market in focus during the forecast period.
Mobile applications may be used to gather self-reported information about symptoms, adherence to medicine, and diet. They can also gather data from other sensors and wearable technology. Digital biomarkers technology, such as mobile applications, record data such as blood pressure, activity tracking, skin conductance, mobility, posture, oxygen levels, glucose monitoring, tremors, sleep, pain, temperature, heart rate, etc. Trends such as digitization (conversion of physical records into digital records), digitalization (introduction of digital records into the healthcare providers' workflow), and digital transformation (adoption of digital business) are also driving the growth of healthcare mobile applications. Thus, such growth in the healthcare mobile applications will boost the growth of the global market during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 57% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The increasing demand for the diagnosis of various diseases, including neurological diseases, cardiac diseases, and others, has boosted the demand for cardiac biomarkers. For instance, an estimated 6.2 million Americans aged 65 years and older were living with Alzheimer's dementia as of March 2021. The number could grow to 13.8 million people by 2060. Thus, the high prevalence of neurological disorders, the growing geriatric population, and high healthcare expenditure for treating chronic diseases are expected to drive market growth in the region during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Alphabet Inc. - The company offers digital biomarkers that provide effective digital measures, starting with engaging, effective devices for accelerating research and development through an end-to-end solution for continuous data capture under the brand Verily.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The Market is driven by the increasing need to monitor hospital patients and individuals with chronic diseases for timely treatment and proactive healthcare. The adoption of wearable devices and digital tools enables continuous patient monitoring, providing valuable insights into physiological data such as glucose levels, blood pressure, and heart rate. Trends include the use of behavioral data to assess emotional health and wellness activities. Challenges lie in addressing critical health concerns and managing the cost-intensive process of digital biomarker implementation, especially in an aging population. There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
The increasing prevalence of CVDs is notably driving the market growth. Cardiovascular diseases are the most prevalent non-communicable diseases worldwide. Other factors that indirectly contribute to the prevalence are smoking, as well as the high prevalence of cardiac arrhythmias, atherosclerosis, diabetes, and high cholesterol. More than half of the affected population resides in low- and middle-income regions. In 2021, the number of people aged 65 years and above across the world was approximately 650 million, and this number is expected to increase to approximately 910 million by 2030. The prevalence of CVDs is also growing due to the increasing growth of risk factors, including diabetes, hypertension, smoking, and obesity.
Moreover, digital biomarkers derived from innovative analysis techniques enable in-depth insights into the cardiac response of cardiac patients during standardized activity. These results open up the possibility for optimized and more patient-tailored treatment strategies that potentially improve the cardiac rehabilitation (CR) outcome. Such factors are expected to increase the demand for digital biomarkers globally during the forecast period.
Growing demand for remote health monitoring is an emerging trend shaping the market growth. The rise in life expectancy of people over the past decade in developed regions such as North America and Western Europe has resulted in an increase in the geriatric population. The growth of the elderly population has led to a rise in the prevalence of chronic diseases, such as diabetes, cancer, arthritis, obesity, asthma, and heart disease. This has resulted in the demand for remote and effective monitoring of health conditions as well as the day-to-day activities of the geriatric population. A rise in the demand for real-time healthcare monitoring among healthcare centers and patients has driven the adoption of digital biomarkers.
In addition, the ability of smartphones and wearable devices to assess healthcare data continuously and integrate data from many sources effectively allows patients to have a better understanding of their condition and make better health decisions. Furthermore, the overall cost of healthcare is reduced because all of these procedures can be carried out remotely without going to a doctor's office or the hospital. Thus, the rising application of digital biomarkers in remote healthcare management will drive the growth of the market in focus during the forecast period.
Low clinical validation of digital biomarkers in mental health is a significant challenge hindering market growth. Despite the potential benefits, the clinical validation of digital biomarkers in mental health is still very low. It can be difficult to provide accuracy, consistency, and relevance to clinical outcomes in people with mental health issues while validating digital biomarkers. To ensure consistency and equity in model predictions, the development of digital biomarkers necessitates the collecting of huge, heterogeneous data sets at scale over extended time periods. It would be difficult to get this data for a single longitudinal study or clinical research. The creation of an open data source has been sought by researchers working in the field of mental health. To improve the capabilities to develop and test digital biomarkers for mental health, the source must aggregate de-identified data.
Additionally, it is still difficult to find suitable control groups for research validating digital mental health solutions. Further study is required to comprehend how these capabilities might be applied therapeutically in mental health to validate clinically applicable measurements and to demonstrate that persons with mental health disorders will accept such solutions. Thus, low clinical validation of digital biomarkers in mental health will negatively impact the growth of the market in focus during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Market Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2023 for the following segments
The Market is witnessing significant growth driven by critical health concerns and the increasing prevalence of chronic diseases, especially among the aging population. This market addresses the cost-intensive process of healthcare by enabling timely treatment through the use of digital tools such as telemedicine and continuous patient monitoring. Health practitioners can monitor vitals and patient-specific parameters remotely, allowing for early detection of baseline changes and potential adverse events. This proactive approach reduces hospital re-admissions and improves patient outcomes. Additionally, digital therapeutics and other digital solutions contribute to enhancing the quality of life for patients by providing personalized healthcare plans and facilitating wellness activities.
Moreover, the market encompasses a wide range of technologies and devices, including digital devices for collecting biometric data such as glucose levels, physical activity, respiratory function, and sleep patterns. These biomarkers offer predictive insights and help identify various disease indications, especially in neurodegenerative disorders, cardiovascular disorders, and respiratory disorders. The market outlook includes geographical regions with potential for growth, offering opportunities for virtual consultations and expanding the sensors market within the monitoring segment. Artificial intelligence and machine learning play a crucial role in data collection and analysis, aiding in the identification of physiological biomarkers and imaging biomarkers. Companies like AliveCor are developing innovative portables such as medical bracelets for monitoring oxygen saturation and cardiovascular disease risk factors, contributing to advancements in drug development and personalized healthcare solutions.
Market Scope |
|
Report Coverage |
Details |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 21.04% |
Market Growth 2024-2028 |
USD 4.43 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
20.34 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 57% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Alphabet Inc., Altoida Inc, Aural Analytics Inc, Brainomix Ltd., Chugai Pharmaceutical Co. Ltd., Clinical Ink Inc., Empatica Inc. , eResearchTechnology GmbH, EVOCAL Health GmbH, F. Hoffmann La Roche Ltd., IMVARIA Inc., Invitrace, IQVIA Holdings Inc., IXICO plc, Koneksa Health Inc., Neurotrack Technologies Inc., PureTech Health Plc, Science Group Plc., VivoSense Inc., and APPLICARE.AI |
Market dynamics |
Parent market analysis, market growth analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.